Skip to main content
Erschienen in: Child's Nervous System 3/2021

12.10.2020 | Original Article

Circulating glial fibrillary acidic protein and ubiquitin carboxy-terminal hydrolase-L1 as markers of neuronal damage in children with epileptic seizures

verfasst von: Marwa Elhady, Eman R Youness, Mones M. AbuShady, Maysa S. Nassar, Ali Abd Elaziz, Mahmoud M Masoud, Fayez K. Foudaa, Walaa Alshasrany Abu Elhamed

Erschienen in: Child's Nervous System | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Epilepsy is a common neurological disease that has a negative impact on physical, social, and cognitive function. Seizure-induced neuronal injury is one of the suggested mechanisms of epilepsy complications. We aimed to evaluate the circulating level of glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase-L1 (UCH-L1) as markers of neuronal damage in children with epilepsy and its relation to epilepsy characteristics.

Study design

Methods

This case control study included 30 children with epilepsy and 30 healthy children as a control group. Seizure severity was determined based on Chalfont score. Serum level of GFAP and UCH-L1were measured, and their associations with epilepsy characteristics were investigated.

Results

Circulating levels of GFAP and UCH-L1 were significantly higher in children with epilepsy than in controls (17.440 ± 6.74 and 5.700 ± 1.64 vs 7.06 ± 3.30 and 1.81 ± 0.23, respectively) especially in those with generalized and active seizures. GFAP and UCH-L1 were significantly correlated to the severity of seizures in the previous 6 months. Elevated GFAP level was a predictor for active seizures (OR 1.841, 95%CI 1.043–3.250, P = 0.035).

Conclusion

Circulating GFAP and UCH-L1 expression is increased in children with epilepsy especially those with active seizures.

Significance

GFAP and UCH-L 1may serve as peripheral biomarkers for neuronal damage in children with epilepsy that can be used to monitor disease progression and severity for early identification of those with drug-resistant epilepsy and those who are in need for epilepsy surgery.
Literatur
1.
Zurück zum Zitat Jones JE, Asato MR, Brown MG, Doss JL, Felton EA, Kearneyet JA et al (2020) Epilepsy benchmarks area IV: limit or prevent adverse consequence of seizures and their treatment across the life span. Epilepsy Curr 20(1_suppl):31S–39SCrossRef Jones JE, Asato MR, Brown MG, Doss JL, Felton EA, Kearneyet JA et al (2020) Epilepsy benchmarks area IV: limit or prevent adverse consequence of seizures and their treatment across the life span. Epilepsy Curr 20(1_suppl):31S–39SCrossRef
2.
Zurück zum Zitat Mao XY, Zhou HH, Jin WL (2019) Redox-related neuronal death and crosstalk as drug targets: focus on epilepsy. Front Neurosci 13:512CrossRef Mao XY, Zhou HH, Jin WL (2019) Redox-related neuronal death and crosstalk as drug targets: focus on epilepsy. Front Neurosci 13:512CrossRef
3.
Zurück zum Zitat Sculier C, Gaínza-Lein M, Sánchez Fernández I, Loddenkemper T (2018) Long-term outcomes of status epilepticus: a critical assessment. Epilepsia 59 Suppl 2(Suppl Suppl 2):155–169CrossRef Sculier C, Gaínza-Lein M, Sánchez Fernández I, Loddenkemper T (2018) Long-term outcomes of status epilepticus: a critical assessment. Epilepsia 59 Suppl 2(Suppl Suppl 2):155–169CrossRef
4.
Zurück zum Zitat Patel DC, Tewari BP, Chaunsali L, Sontheimer H (2019) Neuron–glia interactions in the pathophysiology of epilepsy. Nat Rev Neurosci 20:282–297CrossRef Patel DC, Tewari BP, Chaunsali L, Sontheimer H (2019) Neuron–glia interactions in the pathophysiology of epilepsy. Nat Rev Neurosci 20:282–297CrossRef
5.
Zurück zum Zitat Bishop P, Rocca D, Henley JM (2016) Ubiquitin C-terminal hydrolase L1 (UCH-L1): structure, distribution and roles in brain function and dysfunction. Biochem J 473(16):2453–2462CrossRef Bishop P, Rocca D, Henley JM (2016) Ubiquitin C-terminal hydrolase L1 (UCH-L1): structure, distribution and roles in brain function and dysfunction. Biochem J 473(16):2453–2462CrossRef
6.
Zurück zum Zitat Wang KK, Yang Z, Sarkis G, Torres I, Raghavan V (2017) Ubiquitin C-terminal hydrolase-L1 (UCH-L1) as a therapeutic and diagnostic target in neurodegeneration, neurotrauma and neuro-injuries. Expert Opin Ther Targets 21(6):627–638CrossRef Wang KK, Yang Z, Sarkis G, Torres I, Raghavan V (2017) Ubiquitin C-terminal hydrolase-L1 (UCH-L1) as a therapeutic and diagnostic target in neurodegeneration, neurotrauma and neuro-injuries. Expert Opin Ther Targets 21(6):627–638CrossRef
7.
Zurück zum Zitat Papa L, Mittal MK, Ramirez J, Silvestri S, Giordano P, Braga CF, Tan CN, Ameli NJ, Lopez MA, Haeussler CA, Mendez Giordano D, Zonfrillo MR (2017) Neuronal biomarker ubiquitin C-terminal hydrolase detects traumatic intracranial lesions on computed tomography in children and youth with mild traumatic brain injury. J Neurotrauma 34(13):2132–2140CrossRef Papa L, Mittal MK, Ramirez J, Silvestri S, Giordano P, Braga CF, Tan CN, Ameli NJ, Lopez MA, Haeussler CA, Mendez Giordano D, Zonfrillo MR (2017) Neuronal biomarker ubiquitin C-terminal hydrolase detects traumatic intracranial lesions on computed tomography in children and youth with mild traumatic brain injury. J Neurotrauma 34(13):2132–2140CrossRef
8.
Zurück zum Zitat Yang Z, Wang KK (2015) Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci 38(6):364–374CrossRef Yang Z, Wang KK (2015) Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci 38(6):364–374CrossRef
9.
Zurück zum Zitat Petzold A (2015) Glial fibrillary acidic protein is a body fluid biomarker for glial pathology in human disease. Brain Res 1600:17–31CrossRef Petzold A (2015) Glial fibrillary acidic protein is a body fluid biomarker for glial pathology in human disease. Brain Res 1600:17–31CrossRef
10.
Zurück zum Zitat Hol EM, Pekny M (2015) Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system. Curr Opin Cell Biol 32:121–130CrossRef Hol EM, Pekny M (2015) Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system. Curr Opin Cell Biol 32:121–130CrossRef
11.
Zurück zum Zitat Bazarian JJ, Biberthaler P, Welch RD, Lewis LM, Barzo P, Bogner-Flatz V, Gunnar Brolinson P, Büki A, Chen JY, Christenson RH, Hack D, Huff JS, Johar S, Jordan JD, Leidel BA, Lindner T, Ludington E, Okonkwo DO, Ornato J, Peacock WF, Schmidt K, Tyndall JA, Vossough A, Jagoda AS (2018) Serum GFAP and UCH-L1 for prediction of absence of intracranial injuries on head CT (ALERT-TBI): a multicentre observational study. Lancet Neurol 17(9):782–789CrossRef Bazarian JJ, Biberthaler P, Welch RD, Lewis LM, Barzo P, Bogner-Flatz V, Gunnar Brolinson P, Büki A, Chen JY, Christenson RH, Hack D, Huff JS, Johar S, Jordan JD, Leidel BA, Lindner T, Ludington E, Okonkwo DO, Ornato J, Peacock WF, Schmidt K, Tyndall JA, Vossough A, Jagoda AS (2018) Serum GFAP and UCH-L1 for prediction of absence of intracranial injuries on head CT (ALERT-TBI): a multicentre observational study. Lancet Neurol 17(9):782–789CrossRef
12.
Zurück zum Zitat Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, Hirsch E, Jain S, Mathern GW, Moshé SL, Nordli DR, Perucca E, Tomson T, Wiebe S, Zhang YH, Zuberi SM (2017) ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 58(4):512–521CrossRef Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, Hirsch E, Jain S, Mathern GW, Moshé SL, Nordli DR, Perucca E, Tomson T, Wiebe S, Zhang YH, Zuberi SM (2017) ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 58(4):512–521CrossRef
13.
Zurück zum Zitat Duncan JS, Sander JW (1991) The chalfont seizure severity scale. J Neurol Neurosurg Psychiatry 54(10):873–876CrossRef Duncan JS, Sander JW (1991) The chalfont seizure severity scale. J Neurol Neurosurg Psychiatry 54(10):873–876CrossRef
14.
Zurück zum Zitat Wang KK, Yang Z, Zhu T, Shi Y, Rubenstein R, Tyndall JA et al (2018) An update on diagnostic and prognostic biomarkers for traumatic brain injury. Expert Rev Mol Diagn 18(2):165–180CrossRef Wang KK, Yang Z, Zhu T, Shi Y, Rubenstein R, Tyndall JA et al (2018) An update on diagnostic and prognostic biomarkers for traumatic brain injury. Expert Rev Mol Diagn 18(2):165–180CrossRef
15.
Zurück zum Zitat Mondello S, Palmio J, Streeter J, Hayes RL, Peltola J, Jeromin A (2012) Ubiquitincarboxy-terminal hydrolase L1 (UCH-L1) is increased in cerebrospinal fluid and plasma of patients after epileptic seizure. BMC Neurol 12:85CrossRef Mondello S, Palmio J, Streeter J, Hayes RL, Peltola J, Jeromin A (2012) Ubiquitincarboxy-terminal hydrolase L1 (UCH-L1) is increased in cerebrospinal fluid and plasma of patients after epileptic seizure. BMC Neurol 12:85CrossRef
16.
Zurück zum Zitat Simani L, Elmi M, Asadollahi M (2018) Serum GFAP level: a novel adjunctive diagnostic test in differentiate epileptic seizures from psychogenic attacks. Seizure. 61:41–44CrossRef Simani L, Elmi M, Asadollahi M (2018) Serum GFAP level: a novel adjunctive diagnostic test in differentiate epileptic seizures from psychogenic attacks. Seizure. 61:41–44CrossRef
17.
Zurück zum Zitat Li Y, Wang Z, Zhang B, Zhe X, Wang M, Bai J, Lin T, Zhang S (2013) Cerebrospinal fluid ubiquitin C-terminal hydrolase as a novel marker of neuronal damage after epileptic seizure. Epilepsy Res 103(2–3):205–210CrossRef Li Y, Wang Z, Zhang B, Zhe X, Wang M, Bai J, Lin T, Zhang S (2013) Cerebrospinal fluid ubiquitin C-terminal hydrolase as a novel marker of neuronal damage after epileptic seizure. Epilepsy Res 103(2–3):205–210CrossRef
18.
Zurück zum Zitat Chmielewska N, Maciejak P, Turzyńska D, Sobolewska A, Wisłowska-Stanek A, Kołosowska A et al (2019) The role of UCH-L1, MMP-9, and GFAP as peripheral markers of different susceptibility to seizure development in a preclinical model of epilepsy. J Neuroimmunol 332:57–63CrossRef Chmielewska N, Maciejak P, Turzyńska D, Sobolewska A, Wisłowska-Stanek A, Kołosowska A et al (2019) The role of UCH-L1, MMP-9, and GFAP as peripheral markers of different susceptibility to seizure development in a preclinical model of epilepsy. J Neuroimmunol 332:57–63CrossRef
19.
Zurück zum Zitat Gurnett CA, Landt M, Wong M (2003) Analysis of cerebrospinal fluid glial fibrillary acidic protein after seizures in children. Epilepsia. 44(11):1455–1458CrossRef Gurnett CA, Landt M, Wong M (2003) Analysis of cerebrospinal fluid glial fibrillary acidic protein after seizures in children. Epilepsia. 44(11):1455–1458CrossRef
20.
Zurück zum Zitat Martinian L, Boer K, Middeldorp J, Hol EM, Sisodiya SM, Squier W et al (2009) Expression patterns of glial fibrillary acidic protein (GFAP)-delta in epilepsy-associated lesional pathologies. Neuropathol Appl Neurobiol 35(4):394–405CrossRef Martinian L, Boer K, Middeldorp J, Hol EM, Sisodiya SM, Squier W et al (2009) Expression patterns of glial fibrillary acidic protein (GFAP)-delta in epilepsy-associated lesional pathologies. Neuropathol Appl Neurobiol 35(4):394–405CrossRef
21.
Zurück zum Zitat Stringer JL (1996) Repeated seizures increase GFAP and vimentin in the hippocampus. Brain Res 717(1–2):147–153CrossRef Stringer JL (1996) Repeated seizures increase GFAP and vimentin in the hippocampus. Brain Res 717(1–2):147–153CrossRef
22.
Zurück zum Zitat Zhu M, Chen J, Guo H, Ding L, Zhang Y, Xu Y (2018) High mobility group protein B1 (HMGB1) and interleukin-1β as prognostic biomarkers of epilepsy in children. J Child Neurol 33(14):909–917CrossRef Zhu M, Chen J, Guo H, Ding L, Zhang Y, Xu Y (2018) High mobility group protein B1 (HMGB1) and interleukin-1β as prognostic biomarkers of epilepsy in children. J Child Neurol 33(14):909–917CrossRef
23.
Zurück zum Zitat Deleo F, Thom M, Concha L, Bernasconi A, Bernhardt BC, Bernasconi N (2018) Histological and MRI markers of white matter damage in focal epilepsy. Epilepsy Res 140:29–38CrossRef Deleo F, Thom M, Concha L, Bernasconi A, Bernhardt BC, Bernasconi N (2018) Histological and MRI markers of white matter damage in focal epilepsy. Epilepsy Res 140:29–38CrossRef
24.
Zurück zum Zitat Gan ZS, Stein SC, Swanson R, Guan S, Garcia L, Mehta D, Smith DH (2019) Blood biomarkers for traumatic brain injury: a quantitative assessment of diagnostic and prognostic accuracy. Front Neurol 10:446CrossRef Gan ZS, Stein SC, Swanson R, Guan S, Garcia L, Mehta D, Smith DH (2019) Blood biomarkers for traumatic brain injury: a quantitative assessment of diagnostic and prognostic accuracy. Front Neurol 10:446CrossRef
25.
Zurück zum Zitat McCormack M, McGinty RN, Zhu X, Slattery L, Heinzen EL, EPIGEN Consortium, Costello DJ et al (2020) De-novo mutations in patients with chronic ultra-refractory epilepsy with onset after age five years. Eur J Med Genet 63(1):103625CrossRef McCormack M, McGinty RN, Zhu X, Slattery L, Heinzen EL, EPIGEN Consortium, Costello DJ et al (2020) De-novo mutations in patients with chronic ultra-refractory epilepsy with onset after age five years. Eur J Med Genet 63(1):103625CrossRef
26.
Zurück zum Zitat Atalar AÇ, Vanlı-Yavuz EN, Yılmaz E, Bebek N, Baykan B (2020) Long-term follow-up of a large cohort with focal epilepsy of unknown cause: deciphering their clinical and prognostic characteristics. J Neurol 267(3):838–847CrossRef Atalar AÇ, Vanlı-Yavuz EN, Yılmaz E, Bebek N, Baykan B (2020) Long-term follow-up of a large cohort with focal epilepsy of unknown cause: deciphering their clinical and prognostic characteristics. J Neurol 267(3):838–847CrossRef
Metadaten
Titel
Circulating glial fibrillary acidic protein and ubiquitin carboxy-terminal hydrolase-L1 as markers of neuronal damage in children with epileptic seizures
verfasst von
Marwa Elhady
Eman R Youness
Mones M. AbuShady
Maysa S. Nassar
Ali Abd Elaziz
Mahmoud M Masoud
Fayez K. Foudaa
Walaa Alshasrany Abu Elhamed
Publikationsdatum
12.10.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Child's Nervous System / Ausgabe 3/2021
Print ISSN: 0256-7040
Elektronische ISSN: 1433-0350
DOI
https://doi.org/10.1007/s00381-020-04920-z

Weitere Artikel der Ausgabe 3/2021

Child's Nervous System 3/2021 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.